Related Tags >> Regeneron Pharmaceuticals Sanofi macular degeneration Genentech

Aflibercept News

Most Popular Aflibercept Story

Sanofi, Regeneron's aflibercept flunks PhIII trial

March 11, 2011 — 8:13am ET | By Maureen Martino

Big Pharma's development woes continue. Sanofi-Aventis ($SNY) and partner Regeneron have revealed that their non-small cell lung cancer drug aflibercept (VEGF Trap) given with the chemotherapy Read more...

Aflibercept Press Releases

Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
Following Its Expected Launch Next Year in the U.S. and Europe for Second-Line Treatment of Colorectal Cancer, Regeneron/S
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small
Sanofi-Aventis and Regeneron Pharmaceuticals Cancer Drug Misses Study Goal

Latest Headlines

Regeneron finally captures an FDA OK with new eye drug
November 21, 2011
Sanofi lines up a growing slate of late-stage drug prospects
July 28, 2011
What's the best strategy for working with FDA regulators?
June 15, 2011
Sanofi preps for new pivotal trial of a blockbuster hopeful
June 7, 2011
Sanofi, Regeneron buoyed by Ph3 colon cancer success for aflibercept
April 27, 2011
Sanofi, Regeneron's aflibercept flunks PhIII trial
March 11, 2011
Regeneron to shelve mid-stage cancer drug data
June 12, 2009
Aflibercept misses endpoint in mid-stage study
May 21, 2008
European pipeline likely to stay thin to 2009
January 14, 2008

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events